Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease

被引：22

作者：

Chhabra, Saurabh ^{[1
]}

Jerkins, James H. ^{[1
]}

Conto, John E. ^{[1
]}

Zellner, Katie ^{[1
]}

Shah, Nirav N. ^{[1
]}

Hari, Parameswaran N. ^{[1
]}

Hamadani, Mehdi ^{[1
]}

机构：

[1] Med Coll Wisconsin, Dept Med, Div Hematol, 9200 W Wisconsin Ave,Suite C5500, Milwaukee, WI 53226 USA

来源：

LEUKEMIA & LYMPHOMA | 2020年 / 61卷 / 04期

关键词：

Keratoconjunctivitis sicca; ocular graft-versus-host disease; chronic graft-versus-host disease; dry eyes; topical lifitegrast; DRY EYE DISEASE; CONSENSUS DEVELOPMENT PROJECT; ANTAGONIST SAR 1118; CLINICAL-TRIALS; SOLUTION; 5.0-PERCENT; INTEGRIN ANTAGONIST; AUTOLOGOUS SERUM; DIAGNOSIS; CRITERIA; PLACEBO;

D O I：

10.1080/10428194.2019.1695049

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ocular chronic graft-versus-host disease (oGVHD) is a relatively common complication that occurs following allogeneic hematopoietic cell transplantation. Keratoconjunctivitis sicca (KCS) is the most common manifestation of oGVHD. Lifitegrast is a lymphocyte function-associated antigen-1 antagonist approved to reduce inflammation and symptoms in patients with dry eye disease. We evaluated the efficacy and safety of lifitegrast (5% ophthalmic solution) in patients with ocular GVHD in a single-institution retrospective cohort study of eighteen allogeneic transplant recipients who received topical lifitegrast for oGVHD treatment. The outcome of interest was improvement in oGVHD severity score by National Institutes of Health (NIH) criteria. Lifitegrast was well-tolerated and no serious adverse events were observed. Lifitegrast significantly improved NIH severity scores in 8 (44%) patients. The findings of this study suggest lifitegrast is safe, well-tolerated and is an effective option for oGVHD manifesting as KCS. Prospective evaluation is warranted to confirm efficacy of lifitegrast in this population.

引用

页码：869 / 874

页数：6

共 35 条

[1] Use of Autologous Serum Tears for the Treatment of Ocular Surface Disease From Patients With Systemic Autoimmune Diseases [J].

Ali, Tayyeba K. ;

Gibbons, Allister ;

Cartes, Cristian ;

Zarei-Ghanavati, Siamak ;

Gomaa, Mohamed ;

Gonzalez, Ingrid ;

Gonzalez, Astrid E. ;

Ozturk, Hilal E. ;

Betancurt, Carolina ;

Perez, Victor L. .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2018, 189 :65-70

[2] Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies [J].

Anitua, Eduardo ;

Muruzabal, Francisco ;

Tayebba, Ali ;

Riestra, Ana ;

Perez, Victor L. ;

Merayo-Lloves, Jesus ;

Orive, Gorka .

ACTA OPHTHALMOLOGICA, 2015, 93 (08) :E605-E614

[3] Defining the Intensity of Conditioning Regimens: Working Definitions [J].

Bacigalupo, Andrea ;

Ballen, Karen ;

Rizzo, Doug ;

Giralt, Sergio ;

Lazarus, Hillard ;

Ho, Vincent ;

Apperley, Jane ;

Slavin, Shimon ;

Pasquini, Marcelo ;

Sandmaier, Brenda M. ;

Barrett, John ;

Blaise, Didier ;

Lowski, Robert ;

Horowitz, Mary .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (12) :1628-1633

[4] Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice [J].

Curtis, Lauren M. ;

Datiles, Manuel B., III ;

Steinberg, Seth M. ;

Mitchell, Sandra A. ;

Bishop, Rachel J. ;

Cowen, Edward W. ;

Mays, Jacqueline ;

McCarty, John M. ;

Kuzmina, Zoya ;

Pirsl, Filip ;

Fowler, Daniel H. ;

Gress, Ronald E. ;

Pavletic, Steven Z. .

HAEMATOLOGICA, 2015, 100 (09) :1228-1236

[5] Lifitegrast for the treatment of dry eye disease in adults [J].

Donnenfeld, Eric D. ;

Perry, Henry D. ;

Nattis, Alanna S. ;

Rosenberg, Eric D. .

EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (14) :1517-1524

[6] Graft-versus-host disease [J].

Ferrara, James L. M. ;

Levine, John E. ;

Reddy, Pavan ;

Holler, Ernst .

LANCET, 2009, 373 (9674) :1550-1561

[7] National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report [J].

Filipovich, AH ;

Weisdorf, D ;

Pavletic, S ;

Socie, G ;

Wingard, JR ;

Lee, SJ ;

Martin, P ;

Chien, J ;

Przepiorka, D ;

Couriel, D ;

Cowen, EW ;

Dinndorf, P ;

Farrell, A ;

Hartzman, R ;

Henslee-Downey, J ;

Jacobsohn, D ;

McDonald, G ;

Mittleman, B ;

Rizzo, JD ;

Robinson, M ;

Schubert, M ;

Schultz, K ;

Shulman, H ;

Turner, M ;

Vogelsang, G ;

Flowers, MED .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (12) :945-956

[8] Lifitegrast for the Treatment of Dry Eye Disease Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3) [J].

Holland, Edward J. ;

Luchs, Jodi ;

Karpecki, Paul M. ;

Nichols, Kelly K. ;

Jackson, Mitchell A. ;

Sall, Kenneth ;

Tauber, Joseph ;

Roy, Monica ;

Raychaudhuri, Aparna ;

Shojaei, Amir .

OPHTHALMOLOGY, 2017, 124 (01) :53-60

[9]

Inamoto Yoshihiro, 2019, Biol Blood Marrow Transplant, V25, pe46, DOI 10.1016/j.bbmt.2018.11.021

[10] Validation of Measurement Scales in Ocular Graft-versus-Host Disease [J].

Inamoto, Yoshihiro ;

Chai, Xiaoyu ;

Kurland, Brenda F. ;

Cutler, Corey ;

Flowers, Mary E. D. ;

Palmer, Jeanne M. ;

Carpenter, Paul A. ;

Heffernan, Mary J. ;

Jacobsohn, David ;

Jagasia, Madan H. ;

Pidala, Joseph ;

Khera, Nandita ;

Vogelsang, Georgia B. ;

Weisdorf, Daniel ;

Martin, Paul J. ;

Pavletic, Steven Z. ;

Lee, Stephanie J. .

OPHTHALMOLOGY, 2012, 119 (03) :487-493

← 1 2 3 4 →